Literature DB >> 6235248

Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.

N A Booth, J A Anderson, B Bennett.   

Abstract

Plasma samples from patients with alcoholic cirrhosis were analysed for plasminogen activators and for inhibitors of the fibrinolytic system. Plasminogen activator activity was considerably increased in patients' plasma compared with normal. Immunochemical characterisation of these plasminogen activators showed that they included both tissue type and urokinase type plasminogen activator. The major inhibitor of plasmin, alpha 2-antiplasmin, was decreased in the patients, but no evidence for the generation of plasmin was found.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235248      PMCID: PMC498807          DOI: 10.1136/jcp.37.7.772

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Isolation of plasminogen activator from human plasma by chromatography on lysine-sepharose.

Authors:  R Radcliffe; T Heinze
Journal:  Arch Biochem Biophys       Date:  1978-07       Impact factor: 4.013

2.  The primary inhibitor of plasmin in human plasma.

Authors:  S Müllertz; I Clemmensen
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

5.  Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein.

Authors:  H R Lijnen; M Hoylaerts; D Collen
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  The fibrinolytic enzyme system in hepatic cirrhosis and malignant metastases.

Authors:  D Ogston; N B Bennett; C M Ogston
Journal:  J Clin Pathol       Date:  1971-12       Impact factor: 3.411

8.  Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.

Authors:  C M Ogston; D Ogston
Journal:  J Clin Pathol       Date:  1966-07       Impact factor: 3.411

9.  The alpha2-plasmin inhibitor levels in liver diseases.

Authors:  N Aoki; T Yamanaka
Journal:  Clin Chim Acta       Date:  1978-03-01       Impact factor: 3.786

10.  A study of proteases and protease-inhibitor complexes in biological fluids.

Authors:  A Granelli-Piperno; E Reich
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  13 in total

1.  Bleeding diathesis coincident with chronic myelomonocytic leukaemia.

Authors:  S E Heard; P Revell; L J Holland; A D Hurdle; G F Savidge
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

2.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  Platelet release protein which inhibits plasminogen activators.

Authors:  N A Booth; J A Anderson; B Bennett
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

4.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

5.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

6.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

7.  Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.

Authors:  K Leiper; A Croll; N A Booth; N R Moore; T Sinclair; B Bennett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

8.  Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.

Authors:  K Okabe; I Kato; S Sato; T Kashiwabara; S Furuta; H Sato; K Tanikawa; R Kumashiro; M Kanayama
Journal:  Gastroenterol Jpn       Date:  1992-02

Review 9.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

10.  Initiation of a fibrinolytic system in hepatic resection: the roles of tissue-type plasminogen activator and plasminogen activator inhibitor-1.

Authors:  M Shimada; T Matsumata; K Yamamoto; H Itasaka; A Taketomi; K Sugimachi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.